Evidence map›Paper›PMID 41253409›Full record

ArticleBMJ open respiratory research2025

One-year healthcare trajectories after COVID-19 hospitalisation in patients with chronic respiratory diseases: a nationwide study.

Alexandre Sabaté-Elabbadi, Lucie Brolon, Christian Brun-Buisson, Marie Al Rahmoun, Didier Guillemot, Muriel Fartoukh, Laurence Watier

Abstract read
In one paragraph

Article in BMJ open respiratory research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Alexandre Sabaté-ElabbadiUniversité Paris-Saclay, Université de Versailles St Quentin-en-Yvelines (UVSQ), Institut National de la Santé et de la Recherche Médicale (INSERM) 1018, Centre de Recherche en Épidémiologie et Santé des Populations (CESP), Anti-infective evasion and pharmacoepidemiology Research Team, Montigny-Le-Bretonneux, France alexandre.sabate-elabbadi@pasteur.fr.ORCID http://orcid.org/0000-0003-1103-1040
Lucie BrolonUniversité Paris-Saclay, Université de Versailles St Quentin-en-Yvelines (UVSQ), Institut National de la Santé et de la Recherche Médicale (INSERM) 1018, Centre de Recherche en Épidémiologie et Santé des Populations (CESP), Anti-infective evasion and pharmacoepidemiology Research Team, Montigny-Le-Bretonneux, France.
Christian Brun-BuissonUniversité Paris-Saclay, Université de Versailles St Quentin-en-Yvelines (UVSQ), Institut National de la Santé et de la Recherche Médicale (INSERM) 1018, Centre de Recherche en Épidémiologie et Santé des Populations (CESP), Anti-infective evasion and pharmacoepidemiology Research Team, Montigny-Le-Bretonneux, France.
Marie Al RahmounUniversité Paris-Saclay, Université de Versailles St Quentin-en-Yvelines (UVSQ), Institut National de la Santé et de la Recherche Médicale (INSERM) 1018, Centre de Recherche en Épidémiologie et Santé des Populations (CESP), Anti-infective evasion and pharmacoepidemiology Research Team, Montigny-Le-Bretonneux, France.
Didier GuillemotUniversité Paris-Saclay, Université de Versailles St Quentin-en-Yvelines (UVSQ), Institut National de la Santé et de la Recherche Médicale (INSERM) 1018, Centre de Recherche en Épidémiologie et Santé des Populations (CESP), Anti-infective evasion and pharmacoepidemiology Research Team, Montigny-Le-Bretonneux, France.
Muriel FartoukhSorbonne Université, Assistance Publique - Hôpitaux de Paris, Service de Médecine Intensive Réanimation, Hôpital Tenon, Paris, France.ORCID http://orcid.org/0000-0001-9506-6309
Laurence WatierUniversité Paris-Saclay, Université de Versailles St Quentin-en-Yvelines (UVSQ), Institut National de la Santé et de la Recherche Médicale (INSERM) 1018, Centre de Recherche en Épidémiologie et Santé des Populations (CESP), Anti-infective evasion and pharmacoepidemiology Research Team, Montigny-Le-Bretonneux, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

rationaleCOVID-19 pandemic had a significant impact on patients with chronic respiratory diseases (CRD) and was associated with an increased risk of severe outcomes. However, long-term burden of COVID-19 and the dynamics on healthcare utilisation of patients with CRD remain largely unknown.

objectiveThe objective was to evaluate outcomes and healthcare utilisation trajectories 1 year after hospitalisation for COVID-19 in patients with CRD.

methodsData were extracted from the French National Health Database (SNDS). All adults with CRD who had a first hospitalisation for symptomatic COVID-19 and discharged alive between March 2020 and January 2021 were included. Postdischarge care trajectories, including any hospitalisations and ambulatory care recorded in the SNDS, over a 1-year period, were analysed using state sequence analysis. Healthcare utilisation patterns between the year prior to and the year following hospitalisation were then compared, and a multinomial logistic regression analysis was performed to identify baseline CRD category associated with trajectory clusters.

resultsAmong the 40 066 patients with CRD discharged alive, chronic obstructive pulmonary disease was the main CRD followed by asthma, sleep apnoea and interstitial lung disease. Overall, 6913 (17.3%) died at 1 year. Proportion of days alive spent at home without any care decreased from 91.1% to 64.4%. Five distinct clusters of healthcare trajectories were identified: 'home' (52%) with a slight increase in healthcare utilisation, 'home with care' (22%) with a high healthcare utilisation, 'extended hospitalisation' (9.4%) in long-term care or acute care, 'early death' (11%) and 'late death' (5.1%). Asthma was more often associated with the 'home' trajectory, while other CRD categories were more often associated with other clusters.

conclusionPatients with CRD hospitalised for COVID-19 had heterogeneous 1-year trajectories, characterised by increased healthcare utilisation and risk of death. Asthma was the only CRD category not associated with excess mortality or high healthcare consumption.

Indexed as

COVID-19HospitalizationPatient Acceptance of Health CarePulmonary Disease, Chronic ObstructiveAdultAgedAged, 80 and overAmbulatory CareAsthmaChronic DiseaseFemaleFranceHumansLung Diseases, InterstitialMaleMiddle AgedCOVID-19

Identifiers

PMID41253409
PMCPMC12658480

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.